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Abstract
Small RNAs (sRNAs) are involved in the post-transcriptional regulation of metabolic pathways and in responses to stress and
virulence. We analyzed the expression levels of five sRNAs of Staphylococcus aureus during human colonization or infection.
Total RNA was isolated from nasal carriers, abscesses and cystic fibrosis patients (20 subjects per condition). The expression
levels of the sRNAs were measured in the clinical samples and compared with those of the corresponding strains grown in
vitro. Five sRNAs were encoded and expressed in all clinical strains in vitro. In vivo, the global expression of the five sRNAs
was extremely variable in the abscessed patients, more homogeneous in the cystic fibrosis patients, and highly uniform in
the nasal carrier samples. The expression levels of the sRNAs in vivo resembled those obtained at exponential phase or late
exponential phase of growth in vitro, for three and one sRNA respectively; while for one sRNA, the expression was always
higher in vivo as compared to in vitro growth. The in vitro conditions do not uniformly mimic the in vivo conditions for sRNA
expression. Nasal colonization is associated with a unique expression pattern of sRNA that might reflect the commensalism
of S. aureus in this niche.
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Introduction
Staphylococcus aureus is both a major human pathogen and a
ubiquitous commensal belonging to the normal human flora.
Approximately 20% of the healthy population is colonized
asymptomatically with S. aureus in the nostrils without any
associated disease [1]. However, this pathogen is also responsible
for a wide range of human diseases, from minor skin infections to
life-threatening diseases, such as endocarditis, pneumonia, and
septic shock. It is also one of the leading causes of hospital-
acquired infections, often causing post-surgical wound infections.
The wide diversity of clinical infections caused by S. aureus depends
on the expression of numerous virulence factors, including toxins,
adhesins, enzymes, and immunomodulators [2]. These proteins
are expressed in a coordinated manner under the control of
multiple regulators, such as two-component systems, transcrip-
tional regulatory proteins, secondary metabolites, small peptides
and regulatory RNAs [3,4].
The role of small RNA (sRNAs) in gene regulation has been
established in bacteria [5–8]. In S. aureus, RNAIII was the first
regulatory RNA reported; it has the unique property of acting
both as a mRNA that encodes the 26 aa delta hemolysin (PSM)
peptide, and as the effector molecule of the accessory gene
regulator (agr) system that represses early virulence factors and
activates post-exponentially expressed exotoxins [9,10]. Hence,
RNAIII plays a key role in the quorum sensing-dependant
regulatory networks and coordinately regulates the synthesis of
virulence-associated genes and the transcriptional regulator Rot at
the post-transcriptional level [11–14]. In recent years, bioinfor-
matic approaches coupled with expression analysis [15–17],
cloning/sequencing of small cDNAs [18] and high throughput
sequencing [19,20] have revealed several classes of regulatory
RNAs, including sRNAs, cis-encoded antisense RNAs and cis-
acting regulatory regions of mRNAs. Most of these RNAs are
encoded by the core genome, while several sRNAs are expressed
from mobile elements, pathogenic islands [16,20] and plasmids
[21].
The expression of several sRNAs has been monitored in vitro
using different methods, such as Northern blot or RT-PCR. So
far, no studies have investigated the expression of these sRNAs in
animal models or human infections, except for RNAIII [22,23].
Using real-time reverse transcriptase PCR (RT-PCR), the yield of
RNAIII was measured in the sputum of cystic fibrosis (CF) patients
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colonized with S. aureus. These data revealed that RNAIII was
poorly expressed in the sputum, and no correlation existed
between S. aureus density and RNAIII expression [22]. Further-
more, Loughman et al. [23] showed that the RNAIII transcript
level was reduced in a human cutaneous abscess as compared with
the levels obtained for the corresponding strain at the stationary
phase of growth. However, in invasive abscesses, RNAIII was
detected at a level comparable to that of the corresponding strain
at the stationary phase [23]. In the case of nasal colonization, few
data document RNAIII expression. Burian et al. [24] performed an
analysis of four nasal carriers and showed that agr was not
activated during nose colonization. Taken together, these data
show that it is difficult to predict the expression of sRNAs in vivo. It
is likely that depending on the clinical context, the host-pathogen
interactions influence bacterial gene expression.
In the present study, we determined the expression of several S.
aureus sRNAs during human colonization and infection. To this
end, three different clinical specimens were chosen, namely nose
swabs, sputum from cystic fibrosis patients, and pus from an acute
suppurative cutaneous infection (i.e., abscess). We used RT-PCR
to quantify the well-characterized RNAIII and four recently
described sRNAs (RsaA, RsaE, RsaG and RsaH), representing the
diversity of expression in vitro [15]. These four sRNAs represented
a class of stable and structured non coding RNAs which are
expected to regulate gene expression by a shared mechanism, e.g.
mRNA binding as it was shown for RNAIII [15].
Results
Characteristics of the clinical isolates cultured from the
60 patients
The 60 specimens represented the three categories of S. aureus-
human interaction, namely nasal colonization (20 cases), chronic
infection in cystic fibrosis patients (20 cases) and acute suppurative
cutaneous infection (20 cases). The vast majority of the isolates
were methicillin susceptible (57/60; Table 1), which is consistent
with the low prevalence of community-acquired, methicillin-
resistant S. aureus in France [25]. All 60 isolates were genotyped
using DNA microarrays, targeting 180 genes and 300 alleles (Alere
Technologies). Genotyping was a prerequisite to rule out any
differences in the in vitro expression profiles of the sRNAs that
could reflect differences in the genetic background of the
corresponding isolates. The results showed that the 60 isolates
belong to various clonal complexes (CCs), and the observed CCs
were equally distributed among the three groups (Table 1). An in-
depth analysis using the combinatorial data obtained from the 180
genes showed that each branch of the tree obtained from the 60
isolates most often contained isolates from the three groups of
infection (Figure 1).
The expression of the four sRNAs is different during
culture
The expression of sRNAs in the 60 clinical isolates was assessed
using RT-PCR at the mid (OD600 = 0.5) and late exponential
phase (OD600 = 6) of growth in rich medium (BH). Notably, the
growth curves of the 60 isolates were extremely similar (not
shown). The expression level of each sRNA was normalized
against gyrB mRNA, which is constitutively expressed, and thus
was used as a calibrator [23]. The experiments showed that each
sRNA has a different expression profile. RNAIII and RsaA were
highly expressed, while RsaE and RsaG were both poorly
expressed. As shown in Figure 2, RNAIII, RsaA, RsaG and
RsaH accumulated in the late-exponential phase, as observed for
the laboratory strains RN6390 (sigB deficient) and HG001 (sigB
repaired) (Figure S1). Conversely, the yield of RsaE was
significantly reduced post-exponentially in the clinical isolates
but not in the laboratory strains (Figure S1). The average level of
expression for RNAIII, RsaE and RsaG was similar regardless of
the S. aureus isolate origin (cutaneous abscesses, cystic fibrosis sputa
or nasal swabs), whereas the average level of expression for RsaA
and RsaH was slightly different among the S. aureus strains. For
example, in mid-exponential phase, the average level of RsaA was
statistically lower in the isolates from the cystic fibrosis sputa than
in those from the abscesses (p = 0.013) and nose (p = 0.016). The
expression of RsaH was statistically lower in the abscess isolates in
the mid-exponential phase as compared with the nasal isolates
(p = 0.030). In addition, the expression of RsaH was higher in
abscess isolates in the late-exponential phase compared with the
CF isolates (p = 0.037).
The patterns of sRNA expression during in vitro culture
reveal relatively high and low sRNA-producing isolates
For a given isolate, there was a correlation of the sRNA
expression levels between the mid and late-exponential phases; the
isolate exhibiting a low expression level at the mid-exponential
phase also exhibited a low level of expression at the late-
exponential phase (Figure 2). When considering the distribution
of expression levels for the five sRNAs, each sRNA could be
characterized according to the diversity of the expression level that
remained consistent regardless of the clinical origin of the isolates
(Figures 3A and 3B). The expression level diversity appeared to be
narrow for RsaE, RsaG and RsaH and slightly wider for RsaA,
especially in the CF and nasal isolates. In contrast, the distribution
of RNAIII expression was wide in all clinical situations during the
mid-exponential phase, but the expression profiles were similar
among the isolates grown during the late-exponential phase.
Interestingly, for a given isolate, we observed a link between the
expression levels of the different sRNAs regardless of the origin of
the isolates, e.g., a low RNAIII-expressing isolate also appeared to
express low levels of RsaA, E, G and H (Figures 3A and 3B).
Because these results were established relative to gyrB mRNA, we
asked whether these differences reflected a true variation in sRNA
expression levels or whether the differences were due to variations
in gyrB mRNA. To this end, two additional housekeeping sRNA
genes were selected (4.5S RNA and RNase P) and used as
calibrators to assess the level of expression of RNAIII in 9 isolates
chosen as representatives of the expression level diversity observed
with calibrator gyrB. This experiment revealed that regardless of
the calibrator used, each isolate displayed a similar pattern of
expression, i.e., the low RNAIII expression observed using gyrB as
a calibrator was also observed when 4.5S and RNase P were used
as calibrators (Figure S2).
The expression of sRNAs in clinical samples
To monitor sRNA expression in the host, we analyzed direct
transcripts from clinical samples using RT-PCR. The results were
normalized against the gyrB gene, as in the in vitro studies. All five
sRNAs could be detected in the clinical samples, thus confirming
their in vivo relevance. Strikingly, the expression profiles observed
in vivo (Figure 3C) differed from those in vitro (Figures 3A and 3B).
Furthermore, in contrast with the results obtained in vitro, there
was no link between the expression levels of the various sRNAs
among the isolates in vivo (Figure 3C). The expression levels for the
five sRNAs were extremely variable in abscess samples, more
homogeneous in the cystic fibrosis samples, and uniform in the
nasal samples (Figure 3C). When comparing the abscess and CF
sputa samples, there were no significant differences in the levels of
sRNA expression, except for RsaH (p,0.01). When comparing
sRNA Expression in Clinical Samples
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37294
abscess and nasal samples, the magnitude of the expression was
significantly different for RNAIII, RsaA, RsaE, and RsaH
(p,0.05). A comparison of the CF sputa and nasal samples
revealed that the magnitude of the expression was significantly
different for all five sRNAs (p,0.001).
Comparison of the sRNA expression in bacterial cultures
and human samples
We compared the sRNA expression levels in each sample with
those in the corresponding S. aureus strain grown to mid and late-
exponential phases in vitro (Figures 4A and 4B). These results show
that the yields of RNAIII, RsaA and RsaE in the human samples
resembled those obtained in vitro during mid-exponential phase of
growth. The level of RsaH expression in the clinical samples
corresponded better with that obtained in vitro during the late-
exponential phase of growth. However, for RsaG, the expression
observed in the infected samples was higher than that obtained at
all phases of in vitro growth (Figures 4A and 4B).
Discussion
In general, sRNAs are involved in the post-transcriptional
regulation of different cellular pathways, and some of them have
been implicated in virulence (for a review, see [26,27,28]). Most S.
aureus sRNAs have been identified from a limited number of
laboratory strains, and their expression profiles in human remain
unknown, except for RNAIII, for which the expression in clinical
samples, such as cystic fibrosis sputa or nasal secretions, has been
studied [22–24,29]. The aim of this study was to determine
whether sRNAs are present in clinical isolates, and if their
expression is dependent on colonization or infection in humans.
To this end, we focused on four recently described sRNAs,
representing a diversity of expression patterns [15], and the well-
characterized RNAIII from S. aureus. Two clinical specimens,
Figure 1. Split network tree constructed from the results of the microarray hybridization analysis of the 60 isolates. The tree was
constructed using raw data from the microarrays to visualize the distribution of the strains among different Clonal Complexes. The strains were
assigned the following numbers: Ab1 to Ab20 (in red), abscess strains; CF1 to CF20 (in green), cystic fibrosis sputa strains; No1 to No20 (in blue), nasal
isolates. Multilocus sequence types (ST) and/or clonal complexes (CC) are indicated.
doi:10.1371/journal.pone.0037294.g001
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representing a diversity of clinical conditions were chosen, namely
sputum from cystic fibrosis patients (chronic infection, 20 cases)
and pus from acute suppurative infections requiring surgical
drainage (20 cases). We also analyzed 20 cases of S. aureus nasal
colonization. We observed that all S. aureus isolates were expressed
in all five sRNAs after culture in BH medium to mid or late-
exponential phases of growth. This observation was previously well
documented for RNAIII, which is encoded by virtually all S. aureus
isolates [30]. The observation that all the clinical isolates encoded
the other four sRNAs (RsaA, RsaG, RsaE, RsaH), which were
expressed at various levels, suggests that these sRNAs are
expressed in the core genome of all S. aureus isolates. However,
each sRNA presented its own distinct expression pattern. A
significant correlation, depending on the type of infection or
Table 1. Characteristics of Staphylococcus aureus isolates.
Clonal complex/Agr type
Methicillin susceptibility (Number of
isolates) Samples types
Abscesses* CF sputa* Nose swabs*
CC1/III S (2) 1 1
CC5/II S (9) R (1) 4 4 2
CC7/I S (1) 1
CC8/I S (3) R (2) 1 2 2
CC9/II S (1) 1
CC10/II S (1) 1
CC15/II S (6) 5 1
CC30/III S (6) 4 1 1
CC45/I S (5) 1 3 1
CC59/I S (3) 1 2
CC96/154/III S (1) 1
CC97/I S (2) 1 1
CC121/IV S (2) 2
CC398/I S (12) 4 2 6
ST182/I S (1) 1
ST188/I S (2) 1 1
20 20 20
*n =number of isolates.
doi:10.1371/journal.pone.0037294.t001
Figure 2. Kinetics of sRNA expression in vitro. Clinical S. aureus strains were grown in BH media until mid (OD550 = 0.5) (open triangle) or late-
exponential (OD550 = 6) (plain shape) growth phases. Total RNA was extracted, and the sRNA transcripts were quantified by RT-PCR normalized to the
level of gyrB mRNA expression. The results are presented according to the isolation sites of the 60 strains: 20 abscesses (Ab), 20 cystic fibrosis sputa
(CF) and 20 nasal (No). The results represent the mean of 2 replicate experiments. The bars indicate geometric mean values. *For each sRNA,
statistically significant differences (Mann Whitney, p,0.05) between the level of expression in mid or in late-exponential growth phase and the origin
of the isolate are indicated.
doi:10.1371/journal.pone.0037294.g002
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colonization, could not be assigned to each sRNA, except for RsaA
and RsaH, where a slight but significant difference was detected
depending on the isolation site (Figure 2). These subtle differences
in sRNA expression might reflect subtle differences in the genetic
content of the various isolates. However, such differences could
not be detected using DNA microarrays targeting 180 genes,
which showed that the three groups of isolates were genotypically
indistinguishable (Figure 1). Notably, the nasal isolates could not
be distinguished from the two groups of infection isolates, which is
consistent with other studies showing that the nasal carriage and
clinical isolates of S. aureus belong to the same clades [31].
When considering the sRNA expression kinetics, the most
common pattern was an accumulation in the late-exponential
growth phase, except for RsaE, which accumulated in the mid-
exponential growth phase (Figure 2). RsaE is involved in the
regulation of metabolic enzymes involved in the TCA cycle and
the folate-dependent one-carbon metabolism [15]. Furthermore,
the overexpression of RsaE causes a growth defect that is alleviated
by the non-preferred source acetate [19]. Since RsaE is induced in
a pre-stationary phase in all clinical strains, an expected role for
this sRNA would be to coordinate downregulation of energy
metabolism (TCA cycle), of cofactors, vitamins, and purine
biosynthesis (folate-dependent one-carbon metabolism) to facilitate
adaptation to the entry into stationary phase [15,19]. The
expression of RsaA is under the control of sigmaB, suggesting
that the sRNA might be involved in stress responses, biofilm
formation, and/or virulence (Figure S2), [15]. The functions of
RsaG and RsaH are presently under study. The observed
expression profile of the five sRNAs is similar to that observed
for strain N315 [19] but slightly different from that for strain
RN6390, which carries an rbsU mutation (Figure S2), [15]. Indeed,
the expression of RsaE was higher in the late-exponential phase in
RN6390, while RsaA was poorly expressed. Interestingly, the
repair of sigmaB restored the level of expression of RsaA in strain
HG001 to a level similar that observed in the clinical isolates
(Figure S2), [15]. For RsaE, a similar profile was observed in
strains RN6390 and HG001 (Figure S1), revealing that the
impairment of the sigmaB regulon in strain RN6390 was not
sufficient to explain the altered expression pattern of RsaE. Several
other mutations in the RN6390/8325-4 strain genetic background
[32] might explain these divergent profiles. When comparing the
mean expression levels of the different sRNAs, RNAIII was clearly
the most highly expressed RNA in the late-exponential growth
phase (Figure 2), an observation that could not be attributed to a
better stability of RNAIII since its half-life (459) is in the range of
the four Rsa studied (30–609) [12,15]. However, the expression of
RNAIII varied up to one thousand times among the various
isolates regardless of the calibrator used for comparison (i.e., gyrB,
4.5 S and RNase P) (Figure S2). This variability might reflect the
previous observations that not all S. aureus strains produce
equivalent levels of RNAIII, and that agr+ and agr2 heterogeneous
populations of isolates co-exist [33]. The levels of RNAIII directly
measured in the clinical samples demonstrated that RNAIII is
generally much less expressed in vivo than in cultures grown to late-
exponential phase. This result is observed in all three types of
samples, and similar results have been previously reported in
various clinical samples [22–24]. This result indicates that the cell
density in the clinical samples was probably under the threshold
for agr activation, and corresponds to cultures grown to the mid-
exponential phase rather than to cultures grown to the late-
exponential phase. However, agr-driven quorum sensing does not
explain the kinetics observed for the other sRNAs whose
expression is independent of agr [15].
Overall, the in vivo expression levels of RNAIII, RsaA and RsaE
resembled those obtained during in vitro culture to the mid-
exponential phase, while for RsaG and RsaH, the expression
Figure 3. Expression of S. aureus sRNAs in vitro and in vivo. The expression of the sRNAs was quantified and normalized to the level of gyrB
mRNA expression after in vitro culture to the mid- (panel A) or late-exponential phase (panel B) for the 60 strains, as described in Figure 2, and directly
in the 60 clinical samples (panel C). The values from two separate RT-PCR experiments were used to calculate the mean expression for each point.
*For each sRNA, statistically significant differences (Levene, p,0.05) between the distribution of the expression levels and the origin of the isolate are
indicated.
doi:10.1371/journal.pone.0037294.g003
Figure 4. Comparison of sRNA expression in bacterial cultures and human samples. The results are expressed as the ratio of mRNA
expression levels in vivo versus those in vitro. (A) Fold change in transcript levels for each sRNA in the human samples (circle: abscesses; grey triangle:
cystic fibrosis sputa, black triangle: nasal) relative to the levels in bacteria at the mid-exponential growth phase in BH media. (B) Fold change in
transcript levels for each sRNA in human samples relative to the levels in bacteria at the late-exponential phase in BH media. The bars indicate the
geometric mean values.
doi:10.1371/journal.pone.0037294.g004
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resembles in vitro culture at the late-exponential phase. The major
conclusion drawn from these observations is that in vitro culture,
whatever the stage of growth, does not actually mimic clinical
conditions. These results are consistent with other studies
demonstrating that the level of expression of RNAIII in the cystic
fibrosis sputum was similar to the low-level in vitro expression at the
exponential phase, although protein A, which is directly repressed
by RNAIII [12], did not reach the expected high level of
expression usually observed during the exponential phase [34].
Interestingly, the expression levels of all five sRNAs were
extremely variable in abscess samples, while the samples obtained
from the CF infection and nasal colonization showed modest and
highly uniform sRNA expression, respectively (Figure 3C). This
observation might be due to the fact that the bacteria are exposed
to more quantitatively variable and diverse stresses during acute
infection than during colonization. However, it could also be due
to the inherent variability of the external conditions in abscesses
(e.g., time after onset of infection), whereas such parameters might
be less critical when sampling chronically infected patients or nasal
carriers. The striking uniformity of the sRNA expression observed
in the nasal samples does not result from the intrinsic properties of
the isolates because they display a diversity of expression similar to
the other isolates when grown in vitro (Figure 3A, 3B). We speculate
that the uniform sRNA expression in nasal sample reflects the
perfect adaptation of S. aureus to the anterior nares in which the
bacteria has evolved to minimize the effect of the possible stresses
encountered in this niche. Thus the uniform level of sRNA
expression in nasal colonization might reflect a sort of vigilance
status of the bacteria associated with commensalism. Indeed,
Burian et al. [24] studied the transcriptional response of several
staphylococcal genes from the nose of four persistent carriers and
showed that recA (a key enzyme of the SOS response) and relA (a
key factor of the stringent response) were expressed at lower levels
compared with those found in cells grown in culture medium.In
conclusion, we showed the different expression profiles of five
sRNAs from 60 different S. aureus strains, which were isolated from
acute and chronic infections and nasal colonization. The
expression profiles were rather strain specific and not correlated
to the type of infection from which the bacteria were isolated. The
response of each sRNA was not related to a common culture stage
and was highly variable. The fact that all five sRNAs were
expressed by all of the S. aureus strains observed might indicate that
these sRNAs regulate targets that are conserved among strains.
Studies of their functions are currently underway. The comparison
of infection (acute or chronic) versus colonization suggests that the
sRNA expression levels observed in infection are a consequence of
the great variability of the host response, while colonization is
apparently a more uniform and serene scenario, which might reflect
the fact that S. aureus is primarily a commensal of the anterior
nares.
Materials and Methods
Ethics statement
The approval for the collection of clinical samples was obtained
in accordance with the ethical chart of the ethic committees (Comite´
de protection des personnes Sud-Est IV) rules and in accordance with
French Government regulation (bioethics law 2004-800 of August
6, 2004) which does not require written consent for such study as
long as patients did not manifest an opposition to the study and
that clinical samples are analyzed anonymously. The study was
approved by our institutional board. The collection was declared
by the Ministry of Research under the agreement nuDC-2008-176.
Collection samples and bacterial analysis
Twenty purulent samples were recovered from patients who
presented acute suppurative cutaneous infection requiring drain-
age in the emergency department of Edouard Herriot Hospital
(Lyon, France). Upon abscess drainage, a sample of the pus was
collected and taken to the bacteriology laboratory for culture.
After inoculation of the sample onto a blood agar plate
(bioMe´rieux), Trizol LS reagent (Invitrogen) was added to an
aliquot (<100 to 200 ml) of the sample and the mixture was frozen
at – 80uC until extraction. Twenty sputum samples from CF
patients infected with S. aureus were assayed. The sputum samples
were obtained from patients who repeatedly tested positive for S.
aureus infection for several months, indicating chronic lung
infection. These samples were collected during routine visits at
the pediatric hospital (Lyon, France), and a routine bacteriological
analysis was conducted using established procedures. Subsequent-
ly, an aliquot of the sputum sample was treated with Trizol reagent
and stored at – 80uC until RNA isolation. The nostrils of 20
healthy S. aureus carriers were swabbed using a wool cotton swab
moistened with 250 ml of nuclease-free water. The swab was
immediately transferred to water and vigorously vortexed. A 10 ml
aliquot of the sample was spread onto chromogenic medium
selective for S. aureus (CHROMagar, Biolys). Trizol reagent (1 ml)
was added to the tube containing the swab and vigorously
vortexed. The samples were frozen at – 80uC until RNA isolation.
The antimicrobial susceptibility was determined as recom-
mended by the French Society for Microbiology [35].
Bacterial genomic DNA isolation
Chromosomal DNA were obtained from bacterial cultures
grown in Brain Heart BH medium at 37uC for 3 hours. After
centrifugation at 3,4506 g for 10 min, the bacterial pellet was
resuspended in a Tris-HCL buffer (1 mM) containing Triton X-
100, lysostaphin (1 mg/ml), lysozyme (10 mg/ml), and ribonucle-
ase A. The mixture was incubated at 37uC for 30 min, and
subsequently, proteinase K and buffer AL (DNeasy kit, QIAgen)
were added. The DNA was purified using the QIAcube
instrument (Qiagen) according to the manufacturer’s tissue lysis
protocol.
DNA microarray analysis
The DNA microarray analyses (StaphyType, Alere Technolo-
gies, Jena, Germany) were performed according to the protocol
described by Monecke et al. [36] to characterize the 60 S. aureus
isolates. The DNA microarrays detected a total of 330 target
sequences corresponding to 180 genes and their allelic variants.
The data were interpreted based on the algorithm previously
described [37]. A split network tree was generated using the
modified Parcimony method and the SeaView program version 4
[38].
RNA isolation from human samples
One milliliter of the samples was transferred to tubes containing
Lysing Matrix B (MP Biomedicals). Subsequently, the samples
were lysed using a FastPrep Shaking device (40 seconds at a setting
of 6.0), followed by the purification and precipitation of the RNAs
according to the manufacturer’s recommendations (MP Biomed-
icals). For the nasal swabs, an additional precipitation step was
conducted as described [24]. To remove DNA contamination, all
of the RNA samples were digested with DNase I (Fermentas)
(1 U/1 mg of total RNA at 37uC for 30 min). The absence of
DNA contamination was verified by PCR.
sRNA Expression in Clinical Samples
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RNA isolation from S. aureus isolates
Fresh BH broth was inoculated with an overnight culture to an
initial OD600 of 0.05 and grown to the mid (OD600 = 0.5) or post-
exponential phase (OD600 = 6) at 37uC with shaking (200 rpm).
The bacterial cells were harvested, washed in 10 mM Tris buffer
and diluted to a standard OD600 of 1.0 (ca 10
9 cells/ml). One
milliliter of diluted bacterial suspension was treated with 20 ml
lysostaphin (1 mg/ml). The RNA isolation was performed using
the RNeasy Plus mini kit (QIAGEN) according to the manufac-
turer’s instructions.
Relative quantification of sRNA by RT-PCR
The RNA was quantified using a NanoDrop spectrophotom-
eter, and 1 mg of total RNA was transcribed into cDNA using
Enhanced Avian Reverse Transcriptase (Sigma) or Superscript III
Reverse Transcriptase (Invitrogen) and the specific primers listed
in Table S1. Subsequently, the cDNA was used as a template for
the real-time PCR amplification using a LightCycler instrument
(Roche) and the specific primers shown in Table S1. The
amplification products were detected using SYBR Green. The
relative amounts of amplicons for each gene were determined
using quantitative PCR relative to an internal standard (gyrB
encoding GyraseB subunit, 4.5S encoding the ribosomal 4.5S
subunit or rnpB encoding RibonucleaseP B subunit) [39,40]. The
expression levels of the investigated sRNA were expressed as n-fold
differences relative to the calibrator, which were calculated using
RealQuant software (Roche Diagnostics). After the normalization
of each ncRNA transcripts against the calibrator, the sRNA
expression levels in vivo were expressed as n-fold differences relative
to sRNA levels obtained in vitro. The RT-PCR experiments were
processed in duplicate for each of the clinical samples and
corresponding isolates obtained.
Statistical analysis
The statistical analyses were performed using SPSS software
(version 12.0) and the Mann-Whitney and Levene tests. A value of
p,0.05 was considered to be statistically significant.
Supporting Information
Figure S1 Kinetics of sRNAs expression in vitro in
laboratory strains. Strains RN6390 (sigmaB defective, plain
line) and HG001 (sigmaB restored, dotted line) were grown in BH
media until the mid- (OD550 = 0.5) (open triangle) or late-
exponential (OD550 = 6) (plain triangle) growth phases. Total
RNA was extracted, and the sRNA transcripts were quantified
using RT-PCR normalized to gyrB mRNA expression. The results
represent the mean of 2 replicate experiments.
(TIF)
Figure S2 Kinetics of RNAIII expression in vitro
according to three different calibrators. Nine clinical S.
aureus strains, selected as representatives of the diversity of
expression levels observed using the calibrator gyrB, were grown
in BH media until the mid (OD550 = 0.5) (open shape) and late-
exponential (OD550 = 6) (plain shape) growth phases. Total RNA
was extracted, and the RNAIII transcript levels were quantified
using RT-PCR normalized to gyrB mRNA, 4.5S RNA and rnpB
sRNA expression.
(TIF)
Table S1 primers used for reverse transcription and
qPCR on LightCycler.
(DOCX)
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